MyMD Pharmaceuticals Stock (NASDAQ:MYMD)
Previous Close
$1.82
52W Range
$1.75 - $63.90
50D Avg
$2.00
200D Avg
$5.24
Market Cap
$4.29M
Avg Vol (3M)
$61.81K
Beta
2.69
Div Yield
-
MYMD Company Profile
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
MYMD Performance
Peer Comparison
Ticker | Company |
---|---|
GOVX | GeoVax Labs, Inc. |
GOSS | Gossamer Bio, Inc. |
XBIO | Xenetic Biosciences, Inc. |
LRMR | Larimar Therapeutics, Inc. |
LGND | Ligand Pharmaceuticals Incorporated |
REVB | Revelation Biosciences, Inc. |
RXRX | Recursion Pharmaceuticals, Inc. |
REPL | Replimune Group, Inc. |
SRZN | Surrozen, Inc. |
YS | LakeShore Biopharma Co., Ltd |
LYEL | Lyell Immunopharma, Inc. |
UBX | Unity Biotechnology, Inc. |
KRON | Kronos Bio, Inc. |
PASG | Passage Bio, Inc. |
BOLT | Bolt Biotherapeutics, Inc. |
ORIC | ORIC Pharmaceuticals, Inc. |
KROS | Keros Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
AVIR | Atea Pharmaceuticals, Inc. |
KZR | Kezar Life Sciences, Inc. |
EXAI | Exscientia plc |
LYRA | Lyra Therapeutics, Inc. |
NVCT | Nuvectis Pharma, Inc. |